GLP-1 Drug Safety and Effectiveness Across Different Populations
Analysis of GLP-1 drug safety and effectiveness across different patient populations provides evidence for equitable and appropriate use.
Quick Facts
What This Study Found
Analysis of GLP-1 drug safety and effectiveness across different patient populations provides evidence for equitable and appropriate use.
Key Numbers
120 patients with IBD studied. Gastrointestinal side effects occurred in 11.5% of patients. C-reactive protein levels showed improvement.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Analysis of GLP-1 drug safety and effectiveness across different patient populations provides eviden
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.
- Published In:
- The American journal of gastroenterology, 120(5), 1152-1155 (2025)
- Authors:
- Anderson, Scott R, Ayoub, Malek, Coats, Sarah, McHenry, Scott, Tan, Tingyi, Deepak, Parakkal
- Database ID:
- RPEP-09941
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Analysis of GLP-1 drug safety and effectiveness across different patient populations provides evidence for equitable and appropriate use.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09941APA
Anderson, Scott R; Ayoub, Malek; Coats, Sarah; McHenry, Scott; Tan, Tingyi; Deepak, Parakkal. (2025). Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.. The American journal of gastroenterology, 120(5), 1152-1155. https://doi.org/10.14309/ajg.0000000000003208
MLA
Anderson, Scott R, et al. "Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.." The American journal of gastroenterology, 2025. https://doi.org/10.14309/ajg.0000000000003208
RethinkPeptides
RethinkPeptides Research Database. "Safety and Effectiveness of Glucagon-like Peptide-1 Receptor..." RPEP-09941. Retrieved from https://rethinkpeptides.com/research/anderson-2025-safety-and-effectiveness-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.